Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s stock price hit a new 52-week high during trading on Thursday . The stock traded as high as C$11.40 and last traded at C$0.19, with a volume of 151642 shares trading hands. The stock had previously closed at C$0.19.
Devonian Health Group Price Performance
The company has a market capitalization of C$31.53 million, a P/E ratio of -4.13 and a beta of 0.91. The company has a debt-to-equity ratio of 16.36, a current ratio of 1.07 and a quick ratio of 7.82. The company has a 50 day moving average of C$0.20 and a 200-day moving average of C$0.18.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
Read More
- Five stocks we like better than Devonian Health Group
- Follow Kevin O’Leary into the private markets
- The Crash Has Already Started (Most Just Don’t See It Yet)
- Trump’s AI Secret: 100X Faster Than Nvidia
- Trump Planning to Use Public Law 63-43: Prepare Now
- Your Bank Account Is No Longer Safe
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
